-
Viral Infections
-
COVID-19
-
Therapy Studies
-
APN01-COVID-19
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
-
COMIHY
Hydroxychloroquine for the treatment of mild COVID-19 disease
-
COVARI
A clinical trial to assess the efficacy and safety of PB432 in COVID-19 positive inpatients with acute respiratory insufficiency (ARI)
-
COVID-19 ACTT-EU/UK
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults – Version for European Union/United Kingdom Sites
-
COVID-19 EFC16844
An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19
-
COVID-19 Hydroxychloroquine for COVID-19
Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19
-
COVID-19 XPORT-CoV-1001
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe Covid-19 Infection
- CovidVal01
- COVit
-
GI-HOPE
GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration
-
GS-US-540-5773
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
-
GS-US-540-5774
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
-
RECOVER
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease
-
RuxoCoFlaM
A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation
-
RUXOCOIL
A single-arm, open-label, phase II study of ruxolitinib in Covid-19 patients at risk of developing acute respiratory distress syndrome
-
WHO-SOLIDARITY-GERMANY
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY
-
APN01-COVID-19
-
Impfstudien
Nichts anzuzeigen.
- Prophylaxis Studies
- Antibody Studies
-
Compassionate Use Programme
-
COVID-19 Remdesivir Compassionate Use
Remdesivir compassionate use program
-
COVID-19 Remdesivir Compassionate Use
-
Diagnostic Studies
-
Antigen POC Tests COVID-19
Evaluation of the performance of novel rapid diagnostics for SARS-CoV-2 at point-of-care
-
Antigen POC Tests COVID-19
-
Non-interventional Studies, Biobanking, Registries
-
Aspergillosis in COVID19 on ICU
Pulmonary Aspergillosis in Critically Ill COVID19 Patients in Intensive Care Unit - a Multinational Explorative Trial
- CoPa
- Corona und Kognition
- CORSAAR
- COVID-19 Case-Cluster-Study-Heinsbergstudie
-
COVID-19 LEOSS Register
Lean European Open Survey on SARS-CoV-2
-
COVID-19 Mobile Tests für Köln - Community
COVID-19 Mobile Tests für Köln - Community
-
COVID-19 Mobile Tests für Köln - Uniklinik
COVID-19 Mobile Tests for Cologne
- GPN Register für COVID-19
-
ISI - Improving Diagnosis of Severe Infections in Immunocompromised Patients
Improving Diagnosis of Severe Infections in Immunocompromised Patients (ISI)
-
Kidney in COVID-19
Kidney in Coronavirus Disease 2019 Registry
-
NAPKON HAP
Analysis of pathophysiology and pathology of coronavirus disease 2019 (COVID-19), including chronic morbidity (NAPKON HAP)
-
Pa-COVID-19
Phenotyping platform and logitudinal register for COVID-19 patients at Charité
- ProCoV
-
PROTEGO
Evaluation of the course of COVID-19 disease and perceptions among those tested positive – a prospective and retrospective survey based study
- PROVID-CAPSyS
- PROVID-PROGRESS
- Telemed500-Covid-19
-
Aspergillosis in COVID19 on ICU
-
Master Protocols
-
COVID-19 Clinical Trials Master Protocol
A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients
-
COVID-19 Clinical Trials Master Protocol
- SARS-CoV-2 Best Practice
-
COVARI
A clinical trial to assess the efficacy and safety of PB432 in COVID-19 positive inpatients with acute respiratory insufficiency (ARI)
- PROVID-CAPSyS
- PROVID-PROGRESS
- Telemed500-Covid-19
-
Therapy Studies
- MERS-CoV
- Ebola
- Hepatitis
- HIV / AIDS
- Influenza
- Varizella zoster
-
COVID-19
- Bacterial Infections
- Infektionen bei Immungeschwächten Patienten
- Invasive Pilzinfektionen
- Gastrointestinale Infektionen